For Physicians

Publications

• Radioimmunotherapy for CD20-positive B-cell non-Hodgkin’s lymphoma

  Publication: Community Oncology. 2011 Jan 1;8(1):1-8

  Author(s): Peter Lee, Peter J. Rosen

• Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

  Publication: Journal of Clinical Oncology September 1, 2011 vol. 29 no. 25 3389-3395

  Author(s): Nathan Fowler, Brad S. Kahl, Peter Lee, Jeffrey V. Matous, Amanda F. Cashen, Samuel A. Jacobs, Jeffrey Letzer,Bipinkumar Amin, Michael E. Williams, Sonali Smith, Alfred Saleh, Peter Rosen, Hongliang Shi, Sudha Parasuraman, and Bruce D. Cheson

• A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

  Publication: Clinical Cancer Research May 2010 16; 2677

  Author(s): Peter J. Rosen, Christopher J. Sweeney, Dorothy J. Park, Darrin M. Beaupre, Hongjie Deng, Ian M. Leitch, Poornima Shubhakar, Min Zhu, Kelly S. Oliner, Abraham Anderson, and Lorrin K. Yee

• p120-Catenin Is Transcriptionally Downregulated by FOXC2 in Non–Small Cell Lung Cancer Cells

  Publication: Molecular Cancer Research May 2010 8; 762

  Author(s): Fariborz Mortazavi, Jiabin An, Steven Dubinett and Matthew Rettig(2008 Research Grant Recipients)

• A Phase 2 Trial of Immunotherapy With Mitumprotimut-T (Id-KLH) and GM-CSF Following Rituximab in Follicular B-cell Lymphoma

  Publication: Jnl of Immun Feb/Mar 2010, Vol 33, Iss 2, Z78-184

  Author(s): Koç, Omer N.; Redfern, Charles; Wiernik, Peter H.; Rosenfelt, Fred; Winter, Jane N.; Carter, William D.; Gold, Dan P.; Stewart, Morgan E.; Ghalie, Richard G.; Bender, John F.

• Heart transplantation using bivalirudin as anticoagulant.

  Publication: Interact Cardiovasc Thoracic Surgery 2010 Jan;10(1):150-1. Epub 2009 Oct 1.

Author(s): Simsir SA, Schwarz ER, Czer LS, Hamburg SI.

• Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma

  Publication: ASCO 2010; Abstract 8041

  Author(s): JL Vacirca, PI Acs, BJ Shimkus, PJ Rosen

• A phase 2, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (Mab) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV nonsmall cell lung cancer (NSCLC).

  Publication: ASCO 2010; Abstract 7588

  Author(s): DR Camidge, MS Ballas, S Dubey, M Haigentz, PJ Rosen, JF Spicer, HJ West, GD Shah, H Youssoufian, AC Mita

• A phase I pharmacodynamic and pharmacokinetic study of a ras inhibitor,PRLX 93936 in patients with advanced solid tumors

  Publication: ASCO 2010; Abstract 13042

  Author(s): RK Ramanathan, PJ Rosen, AJ Wagner, S Sahasrabudhe, GJ Weiss, P Lee, M Fuerst, P Robbins, P Litka, DD Von Hoff

• A phase 2, single-arm, open-label study of pralatrexate in patients with aggressive relapsed or refractory b-cell non-Hodgkin’s lymphoma (NHL): Study PDX-015

  Publication: ASCO 2010; Abstract E18568

  Author(s): JE Chang, PJ Rosen, CS Magid Diefenbach, H Kacprowicz, O O’Connor

• ENGAGE-501: phase 2 study investigating the role of epigenetic therapy with entinostat (SNDX-275) in relapsed and refractory Hodgkin’s lymphoma (HL)

  Publication: ASCO 2010; Abstract TPS298

  Author(s): A Younes, PJ Rosen, FJ Hernandez-Ilizaliturri, G Bociek, YL Kasamon, A Copeland, GT Lee

• Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors

  Publication: ASCO 2010; Abstract 3066

  Author(s): PJ Rosen, AW Tolcher, P Lee, M Smitley, M Fuerst, R Spinelli, S Crippa, MG Jannuzzo, S Comis, K Papadopoulos

• Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (Pts) with relapsed malignancies

  Publication: ASCO 2010; Abstract 8147

  Author(s): P Lee, AF Wong, HA Burris, K Papadopoulos, EA Sausville, PJ Rosen, DS Mendelson, JR Infante, A Patnaik, MS Gordon

• Colorectal Cancer: Adjuvant and Neoadjuvant Therapy, Commentary

  Publication: Surgical Oncology; Multidisciplinary Approach to Difficult Problems by Silberman and Silberman, 2010, pages 753-756

  Author(s): Robert Decker, MD

• A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea

  Publication: ASH 2009; Abstract 311

Author(s): Srdan Verstovsek, MD, PhD, Francesco Passamonti,Alessandro Rambaldi, MD, Giovanni Barosi, MD, Peter Rosen, MD, Richard Levy, MD, Edward C Bradley, MD, Lee Schacter, William M Garrett, MBA, Kris Vaddi, Ph.D., Nancy Contel, Elisa Rumi, Elisabetta Gattoni, MD, Mario Cazzola, Hagop Kantarjian, Tiziano Barbui and Alessandro Vannucchi

• Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dosefinding results of the VERTICAL study

  Publication: ASH 2009; Abstract 933

  Author(s): J. Matous, J. Letzer, P. Rosen, S. Noga, N. Fowler, S. Smith, B. Amin, H. Shi, S. Parasuraman, B. Cheson

• Phase II results of Study PX-171-007: A phase Ib/II study of carfilzomib (CFZ), a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors

  Publication: ASCO 2009; Abstract 3515

  Author(s): P. J. Rosen, M. Gordon, P. N. Lee, E. Sausville, K. P. Papadopoulos, A. F. Wong, M. Vallone, L. Kunkel, J. Infante, H. A. Burris
• Pharmacokinetic and pharmacodynamic results of a 4-hr IV administration phase I study with EPC2407, a novel vascular disrupting agent

  Publication: ASCO 2009; Abstract 3569

  Author(s): W. L. Read, P. Rosen, P. Lee, S. Anthony, R. Korn, N. Raghunand, B. Tseng, J. Whisnant, D. Von Hoff, R. Tibes

• LB-259. A Pilot Study Utilizing Molecular Profiling of Patients’ Tumors to Find Potential Targets and Select Treatments for Refractory Cancers

  Publication: AACR 2009; Abstract LB-259.

  Author(s): D. Von Hoff, J. Stephenson, Jr., P. Rosen, D. Loesch, M. Borad, S. Anthony, K. Schroeder, R. Yarian, S. Brown, N. Cantafio, J. Hon, D. Richards, L. Smith, D. Agus, T. Fitch, E. Wasserman, C. Fernandez, S. Green, W. Sutherland, M. Bittner, A. Alarcon, D. Mallery, R. Penny

• Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

  Publication: Lancet 2008 Feb 2;371(9610):362-4.

  Author(s): Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL.

• Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy

  Publication: Haematologica, Vol 94, Issue 4, 518-527 d doi:10.3324/haematol.2008.001347

  Author(s): Daniel Nowak, Emilie Le Toriellec, Marc-Henri Stern, Norihiko Kawamata, Tadayuki Akagi, Martin J. Dyer, Wolf-Karsten Hofmann, Seishi Ogawa H. Phillip Koeffler (2006 Research Grant Recipient)

• AMG 102, an HGF/SF antagonist, in combination with antiangiogenesis targeted therapies in adult patients with advanced solid tumors

  Publication: Jnl of Clin Onc 26: 2008(May 20 suppl;abstr 3570)

  Author(s): P. J. Rosen, C. J. Sweeney, D. J. Park, E. Rasmussen, P. Shubhakar, C. Scripture, I. Leitch, J. Lu, D. M. Beaupre, L. K. Yee

• Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity

  Publication: Jnl of Clin Onc 26: 2008 (May 20 suppl;abstr 2531)

  Author(s): S. P. Anthony, W. Read, P. J. Rosen, R. Tibes, D. Park, D. Everton, B. Tseng, J. Whisnant, D. D. Von Hoff

• Phase II trial of vatalinib in patients with advanced or metastatic pancreatic adenocarcinoma who failed gemcitabine therapy

  Publication: Jnl of Clin Onc 26: 2008 (May 20 suppl;abstr 4615)

  Author(s): T. Dragovich, D. A. Laheru, J. J. Crowley, L. S. Smith, J. Seng, H. A. Burris, III, P. J. Rosen, D. D. Von Hoff, V. Bolejack, M. Hidalgo

• Obatoclax (GX15-070), a small molecule pan-bcl-2 inhibitor, incombination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC)

  Publication: EORTC-NCI-AACR Symposium 2008 ; Abstract 592

  Author(s): A Chiapporil, C Williams, D Northfelt, J Adams, S Malik, M Edelman, P Rosen, D Van Echo, M Berger, EB Haural

• Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

  Publication: Blood, 1 October 2007, Vol. 110, No. 7, pp. 2667-2673.

  Author(s): Norihiko Kawamata, John Chen, and H. Phillip Koeffler(2006 Research Grant Recipient)

• Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 2-Year Update

  Publication: Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 568

  Author(s): James B. Bussel, D.J. Kuter, J.Th.M de Wolf, T.H. Guthrie, A. Newland, J.S. Wasser, S.I. Hamburg, L. Bjorkquist, M. Guo and J. Nichol

• Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum and erlotinib resistant adenocarcinoma of the lung (NSCLA)

  Publication: Jnl of Clin Onc, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7627

  Author(s): E. Massarelli, V. A. Miller, N. B. Leighl, P. J. Rosen, K. S. Albain, L. L. Hart, O. Melnyk, L. Sternas, J. Ackerman, R. S. Herbst

• Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®)

  Publication: Blood (ASH Annual Meeting Abstracts) 2007 110:Abstract 3427

  Author(s): Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD,PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

• Measuring the ability of primary-care physicians to diagnose and manage patients with hematologic malignancies

  Publication: ASH 2007; Abstract 3312

  Author(s): PJ Rosen, RC Wender, H Kadkhoda, SL Kober

• Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses

  Publication: Jnl of Clin Onc 2006 Jul 1;24(19):3107-12.Epub 2006 Jun 5.

  Author(s): Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.

• Phase II study of denileukin diftitox (ONTAK) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL) after failure of = 2 prior therapies

  Publication: ASH 2006; Abstract 4724

  Author(s): Czuczman MS, Pinter-Brown L, Lechowicz MJ, Bartlett N, Lazarus H, Lister J, Goy A, Kahanic S, Rosen P, Acosta M.

• Cancer of the Pancreas: Adjuvant and Neoadjuvant Therapy

  Publication: 2006 Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems. Lippincott, Williams & Wilkins. ed 2 Chap 36 rev.

  Author(s): Park DJ, Lenz H, Rosen PJ

Gaucher and Pompe Disease Program

• A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe’s Disease

  Publication: New England Journal of Medicine 2010, 362:1396-1406

  Author(s): Ans T. van der Ploeg, M.D., Ph.D., Paula R. Clemens, M.D., Deyanira Corzo, M.D., Diana M. Escolar, M.D., Julaine Florence, P.T.,D.P.T., Geert Jan Groeneveld, M.D., Ph.D., Serge Herson, M.D., Priya S. Kishnani, M.D., Pascal Laforet, M.D., Stephen L. Lake, Sc.D., Dale J. Lange, M.D., Robert T. Leshner, M.D., Jill E. Mayhew, P.T., Claire Morgan, M.D., M.P.H., Kenkichi Nozaki, M.D., Ph.D., Dorothy J. Park, M.D., Alan Pestronk, M.D., Barry Rosenbloom, M.D., Alison Skrinar, M.P.H., Carine I. van Capelle, M.D., Nadine A. van der Beek, M.D., Melissa Wasserstein, M.D., and Sasa A. Zivkovic, M.D., Ph.D.

• Multiple Myeloma and Gaucher Genes

  Publication: Genetics in Medicine February 2009-Vol. 11-Issue 2 - p 134

  Author(s): Rosenbloom, Barry E. MD; Becker,Pamela MD;Weinreb,Neal MD

• Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study

  Publication: Clinical Genetics, Vol.73, Number 5, May 2008, p. 430-440(11)

  Author(s): Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, Fitzpatrick MA, Rosenthal D.

• Prevelance of type 1 Gaucher disease in the United States.

  Publication: Arch Itern Med. 2008 Feb 11; 168(3): 326-7

  Author(s):Weinreb NJ, Andersson HC, Banikazemi M, Barranger J, Beutler E, Charrow J, Grabowski GA, HOllak CE, Kaplan P, Mankin H, Mistry PK, Rosenbloom BE, Vom Dahl S, Zimran A,

• Imiglucerase (Cerezyme®) improves quality of life in patients with skeletal manifestations of Gaucher disease

  Publication: Clinical Genetics, Vol. 71, Num. 6, June 2007, p. 576-588(13)

  Author(s): Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM.

• Gaucher disease and cancer incidence: a study from the Gaucher Registry

  Publication: Blood, 15 June 2005, Vol. 105, No. 12, pp. 4569-4572.

  Author(s): Barry E. Rosenbloom, Neal J. Weinreb, Ari Zimran, Katherine A. Kacena, Joel Charrow, and Elizabeth Ward

• Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients

  Publication: Seminars in Hematology October 2004 Vol 41, Suppl 5,5-22

  Author(s): Neal J. Weinreba, Mario C. Aggio, Hans C. Andersson, Generoso Andria, Joel Charrow, Joe T.R. Clarke, Anders Erikson, Pilar Giraldo, Jack Goldblatt, Carla Hollak, Hiroyuki Ida, Paige Kaplan, Edwin H. Kolodny, Pramod Mistry, Gregory M. Pastores, Ricardo Pires, Ainu Prakesh-Cheng, Barry E. Rosenbloom, C. Ronald Scott, Elisa Sobreira, Anna Tylki-Szymanska, Ashok Vellodi, Stephan vom Dahl, Rebecca S. Wappner, Ari Zimran